Bolt Biotherapeutics Inc. (NASDAQ: BOLT)
$0.5232
+0.0082 ( +1.81% ) 318.4K
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Market Data
Open
$0.5232
Previous close
$0.5150
Volume
318.4K
Market cap
$19.65M
Day range
$0.4970 - $0.5210
52 week range
$0.4750 - $1.5600
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 11 | Jun 14, 2024 |
| 4 | Insider transactions | 1 | Jun 14, 2024 |
| defa14a | Other | 1 | May 20, 2024 |
| 3 | Insider transactions | 2 | May 15, 2024 |
| 8-k | 8K-related | 15 | May 14, 2024 |
| 10-q | Quarterly Reports | 57 | May 14, 2024 |
| ars | Annual reports | 1 | Apr 26, 2024 |
| def | Proxies and info statements | 6 | Apr 26, 2024 |
| defa14a | Other | 3 | Apr 26, 2024 |
| s-8 | Registration statements | 5 | Mar 21, 2024 |